What question did this study set out to answer?

The central aim is to develop models for effective Patient Research Advocate (PRA) participation in preclinical cancer research.

April 5, 2026

Abstract 6356: MATCHMAKERS Cancer Grand Challenge Team: Partnership and purpose to maximize patient research advocate involvement in collaborative preclinical research

Key Result

Structured patient research advocate involvement in pre-clinical cancer research fostered mutual respect, trust, and more patient-centered scientific thinking among trainees.

Key Points

The central aim is to develop models for effective Patient Research Advocate (PRA) participation in preclinical cancer research.
Involvement of four PRAs from the USA and Brazil with cancer experience
Monthly meetings and summits to facilitate communication and learning
Coordination between PRAs, trainees, and investigators
Development of shared language and communication tools
PRAs established partnerships with five trainees across four labs
PRA involvement improved understanding of MATCHMAKERS research goals
Trainees expressed greater appreciation for patient needs and scientific relevance

Structured PICO

Population

Four patient research advocates (PRAs) from the USA and Brazil with lived cancer experience and advocacy expertise, and five trainees from four labs.

Intervention

Structured patient research advocate (PRA) involvement in collaborative preclinical cancer research.

Outcome

Development of shared language, context, and communication tools, and strengthening understanding of research goals and patient needs.

Structured patient research advocate involvement in preclinical research fosters mutual respect, trust, and more patient-centered scientific thinking.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Abstract Objectives Patient research advocate (PRA) involvement in clinical trials has increased, yet involvement in pre-clinical research remains limited because pathways for incorporating patient perspectives are not always clear. MATCHMAKERS seeks to build models for effective PRA participation in pre-clinical science. Background Cancer Grand Challenges (CGC), founded by NCI and CRUK, supports global interdisciplinary teams advancing cancer research and requires patient advocate involvement to ensure real-world impact. Launched in 2024, CGC Team MATCHMAKERS includes researchers from 10 institutions across six countries working to crack the code of how T cells recognize cancer cells using structural biology, high-throughput screening, and artificial intelligence to inform predictive immunotherapy tools. Methods Four PRAs from the USA and Brazil contribute lived cancer experience and advocacy expertise. PRAs attend monthly research meetings, PRA meetings, CGC advocate sessions, and annual CGC and MATCHMAKERS summits. The Lead PI and Program Manager attend PRA meetings and coordinate interactions with trainees and investigators to facilitate bidirectional learning and involvement. Results PRAs have partnered with five trainees from four labs, co-developing shared language, context, and communication tools. PRA involvement has strengthened understanding of MATCHMAKERS research goals, while trainees report appreciation of patient needs and translational relevance. Key activities and trainee reflections are summarized in the Table. Conclusions Early experience demonstrates that structured PRA involvement fosters mutual respect, trust, and more patient-centered scientific thinking. Next steps include expanding PRA-trainees partnerships across institutions and contributing to CGC-wide best-practice development for PRA involvement in pre-clinical research. Citation Format: Annie Ellis, Luciana Holtz, Michele Rakoff, Tracy Solak, Matheus O. de Souza, Michael Birnbaum. MATCHMAKERS Cancer Grand Challenge Team: Partnership and purpose to maximize patient research advocate involvement in collaborative preclinical research abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6356.

Bookmark